Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 17/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11471037 | 0.87 | CYP1A2 (0.73) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1908025 | 0.85 | LTA4H (0.66) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22224242 | 0.85 | LTA4H (0.62) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4688901 | 0.85 | CYP1A2 (0.63) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13844819 | 0.85 | LTA4H (0.62) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4695933 | 0.85 | LTA4H (0.56) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4708073 | 0.84 | LTA4H (0.58) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1903146 | 0.84 | LTA4H (0.65) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8736766 | 0.83 | SMN1; SMN2 (0.64) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18612334 | 0.83 | SMN1; SMN2 (0.64) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4726238-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| WO-2008100564-A1 | LTA4H MODULATORS AND USES THEROF | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | claimed |
| EP-1660492-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-20 | — | — | EP | claimed |
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| EP-1660491-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | claimed |
| EP-1868605-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-26 | — | — | EP | claimed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | claimed |
| WO-2006105304-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | claimed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | claimed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | claimed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 3148/4885CYP1A2 682/4885 |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 3977/4885CYP1A2 1204/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 3977/4885CYP1A2 1204/4885 |
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | LTA4H, LTC4S, LTB4R | LTA4H 1/4885KCNH2 2161/4885CYP1A2 1031/4885 |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | LTA4H, LTC4S, LTB4R | LTA4H 1/4885KCNH2 4064/4885CYP1A2 2109/4885 |
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | LTA4H 1/4885KCNH2 3429/4885CYP1A2 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.